NSI-566RSC cell grafts attenuate stroke-induced neurologic impairments.

Abstract

<p>Neurological function was assessed using a battery of neurological tests (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0091408#pone-0091408-g002" target="_blank">Figure 2</a>). All animals displayed normal neurological function at Baseline (i.e., prior to stroke). At day 7 post-stroke, all animals exhibited significant impairment in neurological function, indicating that all animals received successful stroke. At 14 days post-stroke onwards, dose-dependent and timing-dependent effects of the treatment were recognized, in that the improvement in neurological performance was in the order of high dose to zero dose as follows: 20,000 cells/µl (D) >10,000 cells/µl (C) >5,000 cells/µl (B)>vehicle infusion only (A). In addition, over time there was a trend of better improvement, with the most significant improvement seen at 56 days post-stroke. <b>*</b>significant <0.05 vs. other treatment groups within time point; <b>^#</b>significant <0.05 vs. other time points.</p